US Patent

US7417148 — 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Method of Use · Assigned to Wyeth LLC · Expires 2025-12-11 · 0y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of 4-anilino-3-quinolinecarbonitriles, specifically bosutinib monohydrate, for the treatment of chronic myelogenous leukemia (CML).

USPTO Abstract

Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R 1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R 2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1283 — bosutinib-monohydrate
U-1283 — bosutinib-monohydrate
U-3707 — bosutinib-monohydrate
U-3707 — bosutinib-monohydrate
U-1283 — bosutinib-monohydrate

Patent Metadata

Patent number
US7417148
Jurisdiction
US
Classification
Method of Use
Expires
2025-12-11
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.